KU Medical Center part of COVID-19 clinical trial
Share
Tweet
September 23, 2020
KANSAS CITY, Kan. (AP) — The University of Kansas Medical Center is part of a nationwide clinical trial looking into different treatments for patients with mild to moderate symptoms of the coronavirus who do not require hospitalization.
KCUR-FM reports that the first treatment will involve the use of monoclonal antibodies that target the spike proteins of COVID-19, using a drug made by Eli Lilly. Monoclonal antibodies are engineered versions of the same virus-fighting antibodies that the body naturally produces.
The clinical trial is one of at least 40 around the country that seeks to rec...
For access to this article please
sign in or
subscribe.
Reader Comments(0)